Literature DB >> 17220410

Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Jodi M Thomson1, Fabio Prati, Christopher R Bethel, Robert A Bonomo.   

Abstract

Boronic acid transition state inhibitors (BATSIs) with R1 side chains of cefotaxime and ceftazidime were assayed against SHV-1, SHV-2, SHV-5, D104K, and D104K G238S beta-lactamases. The D104K variant was the most susceptible to inhibition by the ceftazidime BATSI (Ki, 730+/-80 nM), while the D104K G238S variant was the most susceptible to the cefotaxime BATSI (Ki, 1.1+/-0.2 microM).

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17220410      PMCID： PMC1855462          DOI： 10.1128/AAC.01293-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Recognition and resistance in TEM beta-lactamase.

Authors:  Xiaojun Wang; George Minasov; Jesús Blázquez; Emilia Caselli; Fabio Prati; Brian K Shoichet
Journal:  Biochemistry       Date:  2003-07-22       Impact factor: 3.162

2.  High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; A M Hujer; M Bonafede; R Hutton; C Hoyen; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.

Authors:  R A Powers; E Caselli; P J Focia; F Prati; B K Shoichet
Journal:  Biochemistry       Date:  2001-08-07       Impact factor: 3.162

4.  TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis.

Authors:  X Raquet; J Lamotte-Brasseur; E Fonzé; S Goussard; P Courvalin; J M Frère
Journal:  J Mol Biol       Date:  1994-12-16       Impact factor: 5.469

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins.

Authors:  Andrea M Hujer; Kristine M Hujer; Marion S Helfand; Vernon E Anderson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Role of Asp104 in the SHV beta-lactamase.

Authors:  Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Jodi M Thomson; Mark W Ruszczycky; Vernon E Anderson; Marianne Pusztai-Carey; Magdalena Taracila; Marion S Helfand; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

8.  Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance.

Authors:  A M Hujer; K M Hujer; R A Bonomo
Journal:  Biochim Biophys Acta       Date:  2001-05-05

9.  Structure-based approach for binding site identification on AmpC beta-lactamase.

Authors:  Rachel A Powers; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-07-18       Impact factor: 7.446

10.  Comparison of beta-lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinase.

Authors:  Tao Sun; Michiyoshi Nukaga; Kayoko Mayama; Emory H Braswell; James R Knox
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725
View more
  8 in total

1.  Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.

Authors:  Donatella Tondi; Samuele Calò; Brian K Shoichet; Maria Paola Costi
Journal:  Bioorg Med Chem Lett       Date:  2010-04-09       Impact factor: 2.823

2.  Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Authors:  Wei Ke; Jared M Sampson; Claudia Ori; Fabio Prati; Sarah M Drawz; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

3.  Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2.

Authors:  Ben A Shurina; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-04

4.  Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design.

Authors:  Laura J Rojas; Magdalena A Taracila; Krisztina M Papp-Wallace; Christopher R Bethel; Emilia Caselli; Chiara Romagnoli; Marisa L Winkler; Brad Spellberg; Fabio Prati; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

5.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

6.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

Review 7.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965.

Authors:  Toby A Dite; Christopher G Langendorf; Ashfaqul Hoque; Sandra Galic; Richard J Rebello; Ashley J Ovens; Lisa M Lindqvist; Kevin R W Ngoei; Naomi X Y Ling; Luc Furic; Bruce E Kemp; John W Scott; Jonathan S Oakhill
Journal:  J Biol Chem       Date:  2018-04-25       Impact factor: 5.157
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.